Repurposing Pentoxifylline for FGFR3 Downstream Inhibition

Pentoxifylline, beyond its phosphodiesterase inhibition, demonstrates potent STAT1 pathway suppression through direct protein-protein interaction disruption. The drug reduces FGFR3-mediated growth plate senescence by blocking STAT1 nuclear translocation and reducing p21/p16 cyclin-dependent kinase inhibitor expression, allowing continued chondrocyte proliferation despite mutant receptor signaling.